デフォルト表紙
市場調査レポート
商品コード
1543990

抗精神病薬の世界市場

Antipsychotic Drugs

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=153.85円
抗精神病薬の世界市場
出版日: 2024年08月29日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

抗精神病薬の世界市場は2030年までに273億米ドルに達する見込み

2023年に173億米ドルと推定される抗精神病薬の世界市場は、2023年から2030年にかけてCAGR 6.7%で成長し、2030年には273億米ドルに達すると予測されます。本レポートで分析しているセグメントの1つである第二世代抗精神病薬は、CAGR 7.3%を記録し、分析期間終了時には157億米ドルに達すると予測されています。第一世代抗精神病薬セグメントの成長率は、分析期間中CAGR 6.0%と推定されます。

米国市場は45億米ドル、中国はCAGR 10.1%で成長予測

米国の抗精神病薬市場は、2023年に45億米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2023-2030年のCAGRを10.1%として、2030年までに市場規模が66億米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.4%と6.1%と予測されています。欧州では、ドイツがCAGR 4.2%で成長すると予測されています。

世界の抗精神病薬市場- 主要動向と促進要因まとめ

抗精神病薬とは何か?

抗精神病薬は、主に妄想や幻覚、統合失調症や双極性障害などの精神病を管理するために使用される薬です。これらの薬は、脳内の神経伝達物質、特に精神病症状の病態生理学に関与しているドーパミンとセロトニンの作用を変化させることによって機能します。抗精神病薬には、定型抗精神病薬(第一世代)と非定型抗精神病薬(第二世代)の2つの主要なカテゴリーがあります。ハロペリドールやクロルプロマジンなどの定型抗精神病薬は1950年代に開発され、主にドパミン受容体を標的とします。リスペリドン、オランザピン、アリピプラゾールなどの非定型抗精神病薬は後に登場し、ドパミン受容体とセロトニン受容体の両方に作用し、運動障害に関する副作用が少ないことが多いです。これらの薬物は、精神病エピソードの重症度を軽減し、重度の精神疾患を持つ人々の生活の質を向上させる上で極めて重要です。

抗精神病薬はどのように処方、投与されるのですか?

抗精神病薬の処方と投与は、特定の診断、症状の重症度、治療に対する患者の反応などの要素を考慮し、患者の個々のニーズに合わせて行われます。これらの薬剤は、錠剤、カプセル剤、液剤の形で経口投与されるか、長時間作用型の注射剤によって投与されます。長時間作用型注射剤(LAI)は、治療薬レベルを長期にわたって維持できるため、服薬アドヒアランスを高め、入院の頻度を減らすことができると人気を集めています。治療レジメンは多くの場合、低用量から開始し、副作用を最小限に抑えるために徐々に増量していきます。潜在的な副作用を管理し、必要に応じて投与量を調整するためには、ヘルスケア専門家による定期的なモニタリングが不可欠です。さらに、抗精神病薬治療は精神療法やその他の支持療法と併用されることが多く、精神疾患を管理するための全体的なアプローチを提供します。

抗精神病薬開発の最新動向は?

抗精神病薬の開発は急速に発展している分野であり、有効性の向上と副作用の軽減を目指した継続的な研究と技術革新がその原動力となっています。重要な動向のひとつは、治療効果を高めるために異なる神経伝達系や特定の受容体サブタイプを標的とした、新規の作用機序を有する薬剤の開発に焦点が当てられていることです。個別化医療のアプローチもまた、遺伝子やバイオマーカーの研究によって、個々の患者のプロファイルに基づいた、よりオーダーメイドの治療が可能になり、支持を集めています。もう一つの動向は、症状や服薬アドヒアランスをリアルタイムでモニターするための、モバイルアプリやウェアラブルデバイスなどのデジタルヘルス技術の統合です。また、抗精神病薬と他の薬理学的薬剤や認知行動療法(CBT)のような非薬理学的介入を組み合わせた補助療法の探求も顕著です。こうした動向は、革新的で患者中心のアプローチによってメンタルヘルス治療を推進するという、より広範なコミットメントを反映しています。

何が抗精神病薬市場の成長を牽引しているのか?

抗精神病薬市場の成長はいくつかの要因によって牽引されており、それぞれが抗精神病薬の需要増加と採用に寄与しています。主な要因の1つは、世界的に精神疾患の有病率が上昇していることであり、効果的な抗精神病薬治療の必要性が高まっています。長時間作用型注射剤やデジタルヘルスツールなど、ドラッグの製剤化とデリバリーにおける技術の進歩は、患者のアドヒアランスと治療成績を向上させる。精神疾患の遺伝的・分子的基盤の解明は、より的を絞った効果的な薬剤の開発を後押ししています。さらに、精神衛生問題の非正統化と啓発キャンペーンの高まりは、早期診断と早期治療につながり、患者基盤を拡大します。また、プライマリ・ケアや広範なヘルスケア・インフラへのメンタルヘルス・サービスの統合も、抗精神病薬へのアクセスを容易にしています。さらに、製薬会社による研究開発への多額の投資と公衆衛生への取り組みが、抗精神病薬市場の継続的な進化を支えています。これらの要因が相まって、抗精神病薬は力強い成長軌道を描いており、重度の精神疾患を抱える人々の複雑で多様なニーズに対応しています。

調査対象企業の例(注目の44社)

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol Meyer Squibb Company
  • AstraZeneca
  • Glaxo SmithKline Plc
  • Allergan

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP10320

Global Antipsychotic Drugs Market to Reach US$27.3 Billion by 2030

The global market for Antipsychotic Drugs estimated at US$17.3 Billion in the year 2023, is expected to reach US$27.3 Billion by 2030, growing at a CAGR of 6.7% over the analysis period 2023-2030. Second Generation Antipsychotic Drugs, one of the segments analyzed in the report, is expected to record a 7.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in the First Generation Antipsychotic Drugs segment is estimated at 6.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$4.5 Billion While China is Forecast to Grow at 10.1% CAGR

The Antipsychotic Drugs market in the U.S. is estimated at US$4.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$6.6 Billion by the year 2030 trailing a CAGR of 10.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global Antipsychotic Drugs Market - Key Trends and Drivers Summarized

What Are Antipsychotic Drugs and How Do They Work?

Antipsychotic drugs are medications used primarily to manage psychosis, including delusions, hallucinations, and disorders such as schizophrenia and bipolar disorder. These drugs function by altering the effects of neurotransmitters in the brain, particularly dopamine and serotonin, which are implicated in the pathophysiology of psychotic symptoms. There are two main categories of antipsychotic drugs: typical (first-generation) and atypical (second-generation). Typical antipsychotics, such as haloperidol and chlorpromazine, were developed in the 1950s and primarily target dopamine receptors. Atypical antipsychotics, such as risperidone, olanzapine, and aripiprazole, emerged later and act on both dopamine and serotonin receptors, often with fewer side effects related to movement disorders. These medications are crucial in reducing the severity of psychotic episodes, improving the quality of life for individuals with severe mental health conditions.

How Are Antipsychotic Drugs Prescribed and Administered?

The prescription and administration of antipsychotic drugs are tailored to the individual needs of patients, considering factors such as the specific diagnosis, symptom severity, and patient response to treatment. These medications can be administered orally in the form of tablets, capsules, or liquid solutions, or through long-acting injectable formulations. Long-acting injectables (LAIs) have gained popularity due to their ability to maintain therapeutic drug levels over extended periods, enhancing adherence and reducing the frequency of hospitalizations. The treatment regimen often begins with a low dose that is gradually increased to minimize side effects. Regular monitoring by healthcare professionals is essential to manage potential adverse effects and adjust dosages as necessary. Additionally, antipsychotic treatment is frequently combined with psychotherapy and other supportive measures to provide a holistic approach to managing mental health disorders.

What Are the Latest Trends in Antipsychotic Drug Development?

The development of antipsychotic drugs is a rapidly evolving field, driven by ongoing research and innovation aimed at improving efficacy and reducing side effects. One significant trend is the focus on developing drugs with novel mechanisms of action, targeting different neurotransmitter systems or specific receptor subtypes to enhance therapeutic outcomes. Personalized medicine approaches are also gaining traction, with genetic and biomarker studies informing more tailored treatments based on individual patient profiles. Another trend is the integration of digital health technologies, such as mobile apps and wearable devices, to monitor symptoms and medication adherence in real time. The exploration of adjunctive therapies, combining antipsychotic drugs with other pharmacological agents or non-pharmacological interventions like cognitive-behavioral therapy (CBT), is also prominent. These trends reflect a broader commitment to advancing mental health treatment through innovative and patient-centered approaches.

What Is Driving the Growth in the Antipsychotic Drug Market?

The growth in the antipsychotic drug market is driven by several factors, each contributing to the increasing demand and adoption of these medications. One of the primary drivers is the rising prevalence of mental health disorders globally, which underscores the need for effective antipsychotic treatments. Technological advancements in drug formulation and delivery, such as long-acting injectables and digital health tools, enhance patient adherence and therapeutic outcomes. The expanding understanding of the genetic and molecular underpinnings of psychiatric disorders propels the development of more targeted and effective drugs. Furthermore, the destigmatization of mental health issues and increasing awareness campaigns lead to earlier diagnosis and treatment, thereby expanding the patient base. The integration of mental health services into primary care settings and the broader healthcare infrastructure also facilitates access to antipsychotic medications. Additionally, significant investments in research and development by pharmaceutical companies and public health initiatives support the continuous evolution of the antipsychotic drug market. Collectively, these factors create a robust growth trajectory for antipsychotic medications, addressing the complex and diverse needs of individuals with severe mental health conditions.

Select Competitors (Total 44 Featured) -

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol Meyer Squibb Company
  • AstraZeneca
  • Glaxo SmithKline Plc
  • Allergan

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Antipsychotic Drugs - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Mental Health Disorders Spurs Market Growth
    • Technological Advancements Propel Growth in Antipsychotic Drug Development
    • Novel Mechanisms of Action Expand Addressable Market Opportunity
    • Personalized Medicine Approaches Strengthen Business Case for Tailored Treatments
    • Adjunctive Therapies Accelerate Demand for Combined Treatment Regimens
    • Long-Acting Injectables Sustain Growth by Enhancing Patient Compliance
    • Increasing Awareness and Destigmatization Throw Spotlight on Antipsychotic Treatments
    • Expansion of Mental Health Services into Primary Care Drives Market Expansion
    • Improved Understanding of Psychiatric Disorders Propels Market Demand
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Second Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Second Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for First Generation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for First Generation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Schizophrenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Bipolar Disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Bipolar Disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Dementia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Dementia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 22: World Antipsychotic Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: World 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • JAPAN
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • CHINA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: China 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: China 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • EUROPE
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Antipsychotic Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: France 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: France 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • GERMANY
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Antipsychotic Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • AUSTRALIA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • INDIA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 116: India Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: India 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 119: India Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: India 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Antipsychotic Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Antipsychotic Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • IRAN
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030
  • AFRICA
    • Antipsychotic Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Antipsychotic Drugs by Therapeutic Class - Second Generation and First Generation Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Antipsychotic Drugs by Therapeutic Class - Percentage Breakdown of Value Sales for Second Generation and First Generation for the Years 2014, 2024 & 2030
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Antipsychotic Drugs by Application - Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Antipsychotic Drugs by Application - Percentage Breakdown of Value Sales for Schizophrenia, Bipolar Disorder, Dementia, Depression and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION